MDS Pharma introduces new Phase I study management system

According to the company, the new version of the ClinQuick system includes a more user-friendly interface, improved menu navigation and a more robust data platform. This new platform is expected to enable faster and more flexible reporting and will ultimately allow clients to access their data via the internet.

MDS Pharma’s ClinQuick system facilitates rapid data cleansing and client monitoring for seamless operation of both single and multi-site studies. The company also said that the new ClinQuick accelerates timelines, enables accurate direct data acquisition, and reduces costs by a third compared to traditional paper case report forms – the forms used by clients to collect and document data from each participating clinical research site.

David Spaight, president of MDS, said: “Our investment to enhance the ClinQuick system builds on that legacy of success and will allow us to meet growing client demand for early clinical research services while maintaining our leadership position in Phase I. This next-generation ClinQuick system will further improve our ability to deliver high quality Phase I services on time.”